{"id":10203,"date":"2026-07-07T08:37:54","date_gmt":"2026-07-07T13:37:54","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10203"},"modified":"2026-07-07T10:59:27","modified_gmt":"2026-07-07T15:59:27","slug":"catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","title":{"rendered":"Catalent y Nanoscope Therapeutics ampl\u00edan su colaboraci\u00f3n para respaldar el desarrollo en fase avanzada y el suministro comercial de la principal terapia g\u00e9nica optogen\u00e9tica, MCO-010."},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10203\" class=\"elementor elementor-10203\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong><span class=\"legendSpanClass\">DALLAS<\/span>,\u00a0<span class=\"legendSpanClass\">7 de julio de 2026<\/span><\/strong>\u00a0\u2014\u00a0<a href=\"https:\/\/www.catalent.com\/\" target=\"_blank\" rel=\"nofollow noopener\">Catalent<\/a>, l\u00edder en facilitar el desarrollo y suministro de mejores tratamientos para pacientes en todo el mundo, y\u00a0<a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Terap\u00e9utica del nanoscopio<\/a>, Nanoscope, una empresa de biotecnolog\u00eda comprometida con la comercializaci\u00f3n de terapias novedosas, aplicables a cualquier enfermedad y que restauran la visi\u00f3n en pacientes con p\u00e9rdida de fotorreceptores debido a degeneraciones retinianas, anunci\u00f3 hoy una ampliaci\u00f3n de su colaboraci\u00f3n para respaldar la fase cl\u00ednica avanzada y el suministro comercial de la principal terapia g\u00e9nica optogen\u00e9tica de Nanoscope, MCO-010.<\/p><p>En el marco de esta alianza ampliada, Catalent proporcionar\u00e1 el embalaje y la distribuci\u00f3n de MCO-010 conformes a la normativa comercial y ha obtenido el programa de validaci\u00f3n de embalaje comercial para respaldar la solicitud de licencia de productos biol\u00f3gicos (BLA) de Nanoscope. Actualmente se est\u00e1 llevando a cabo un proceso continuo de presentaci\u00f3n de solicitudes ante la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos (FDA).<\/p><p>\u201cEn Catalent nos complace ampliar nuestra colaboraci\u00f3n con Nanoscope a medida que MCO-010 avanza hacia su posible comercializaci\u00f3n\u201d, declar\u00f3 Ricky Hopson, presidente del grupo de Servicios Cl\u00ednicos y Especializados y jefe de Gabinete. \u201cEn Catalent nos comprometemos a apoyar a Nanoscope en cada etapa del proceso para llevar esta innovadora terapia al mercado y contribuir a que la misi\u00f3n de Nanoscope de restaurar la visi\u00f3n se convierta en realidad para pacientes de todo el mundo\u201d.\u201d<\/p><p>\u201cA medida que continuamos fabricando el f\u00e1rmaco comercial MCO-010, contar con un socio de envasado que pueda escalar con nosotros para satisfacer las necesidades de la comercializaci\u00f3n global es fundamental\u201d, declar\u00f3 Sulagna Bhattacharya, cofundadora y directora ejecutiva de Nanoscope Therapeutics. \u201cLa experiencia y la fiabilidad de Catalent nos dan confianza mientras nos preparamos para la siguiente etapa de este proyecto, y esperamos continuar esta colaboraci\u00f3n para ofrecer una opci\u00f3n de tratamiento muy necesaria a los pacientes que padecen enfermedades degenerativas de la retina\u201d.\u201d<\/p><p>MCO-010 se est\u00e1 desarrollando para restaurar la visi\u00f3n en pacientes con enfermedades degenerativas avanzadas de la retina, como la retinosis pigmentaria y la enfermedad de Stargardt, mediante la reprogramaci\u00f3n de las c\u00e9lulas retinianas para que sean sensibles a la luz. Este enfoque est\u00e1 dise\u00f1ado para tratar a pacientes con la enfermedad en fase avanzada que actualmente tienen opciones terap\u00e9uticas limitadas.<\/p><p><b>Acerca de Catalent<\/b><\/p><p>Catalent, Inc. es una organizaci\u00f3n l\u00edder mundial en desarrollo y fabricaci\u00f3n por contrato (CDMO) que impulsa misiones que ayudan a las personas a vivir vidas mejores y m\u00e1s saludables. Cada producto que Catalent ayuda a desarrollar, fabricar y lanzar refleja su compromiso de mejorar los resultados de salud en todo el mundo a trav\u00e9s de su enfoque &quot;El paciente primero&quot;. Catalent ofrece un servicio incomparable a clientes de la industria farmac\u00e9utica, biotecnol\u00f3gica y de salud del consumidor, cumpliendo con sus misiones de transformar vidas. Catalent dise\u00f1a soluciones integrales para satisfacer las necesidades de los clientes en todas las fases de desarrollo y fabricaci\u00f3n. Con miles de cient\u00edficos y t\u00e9cnicos y las plataformas tecnol\u00f3gicas m\u00e1s avanzadas en casi 40 centros globales, Catalent suministra miles de millones de dosis de tratamientos que mejoran y salvan vidas a pacientes cada a\u00f1o. Para obtener m\u00e1s informaci\u00f3n, visite\u00a0<a href=\"http:\/\/www.catalent.com\" target=\"_blank\" rel=\"nofollow noopener\">www.catalent.com<\/a>.<\/p><p><b>Acerca de Nanoscope Therapeutics<\/b><\/p><p><a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Terap\u00e9utica del nanoscopio<\/a>\u00a0est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (RP) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y planea iniciar una\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">Ensayo de registro de fase 3<\/a>\u00a0En 2026, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, as\u00ed como las designaciones Sakigake y hu\u00e9rfana de la PMDA para distrofias retinianas hereditarias (IRD) y las designaciones hu\u00e9rfana de la EMA y la SFDA para IRD. Se espera que un programa de fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience en 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p><p><b>Contacto:<\/b><\/p><p>Catalent<br \/><a href=\"mailto:media@catalent.com\" target=\"_blank\" rel=\"nofollow noopener\">media@catalent.com<\/a><\/p><p>Nanoscope Therapeutics, Inc<br class=\"dnr\" \/>+1 (817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p><p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>DALLAS,\u00a0July 7, 2026\u00a0&#8212;\u00a0Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and\u00a0Nanoscope Therapeutics, a biotechnology company committed to commercializing novel, disease-agnostic, vision-restoring therapies for patients with photoreceptor loss due to retinal degenerations, today announced an expanded partnership to support late-phase clinical and commercial supply of Nanoscope&#8217;s lead optogenetic gene [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10204,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10203","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T13:37:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-07T15:59:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010\",\"datePublished\":\"2026-07-07T13:37:54+00:00\",\"dateModified\":\"2026-07-07T15:59:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\"},\"wordCount\":608,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Catalent_V4FIN.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\",\"name\":\"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Catalent_V4FIN.jpg\",\"datePublished\":\"2026-07-07T13:37:54+00:00\",\"dateModified\":\"2026-07-07T15:59:27+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Catalent_V4FIN.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Catalent_V4FIN.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","og_locale":"es_MX","og_type":"article","og_title":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-07-07T13:37:54+00:00","article_modified_time":"2026-07-07T15:59:27+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010","datePublished":"2026-07-07T13:37:54+00:00","dateModified":"2026-07-07T15:59:27+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/"},"wordCount":608,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Catalent_V4FIN.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","url":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","name":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Catalent_V4FIN.jpg","datePublished":"2026-07-07T13:37:54+00:00","dateModified":"2026-07-07T15:59:27+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Catalent_V4FIN.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Catalent_V4FIN.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10203"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10203\/revisions"}],"predecessor-version":[{"id":10211,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10203\/revisions\/10211"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10204"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}